constructs 64624 (Addgene inc)
Structured Review
Constructs 64624, supplied by Addgene inc, used in various techniques. Bioz Stars score: 92/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/p38+construct/p38+WT+O%2FE+(MAPK14)-pcw107-V5+(Plasmid+%2364624)/pmc10948969-720-25-24
Average 92 stars, based on 1 article reviews
Images
Related Articles
Mutagenesis:Article Title: WNTinib is a multi-kinase inhibitor with specificity against β-catenin mutant hepatocellular carcinoma. Article Snippet: Alex Rialdi, Mary Duffy, Alex P. Scopton, Frank Fonseca, Julia Nanyi Zhao , Megan Schwarz, Pedro Molina-Sanchez, Slim Mzoughi, Elisa Arceci, Jordi Abril-Fornaguera , Austin Meadows, Marina Ruiz de Galarreta, Denis Torre, Kyna Reyes, Yan Ting Lim, Felix Rosemann , Zaigham M. Khan , Kevin Mohammed, Xuedi Wang, Xufen Yu , Manikandan Lakshmanan, Ravisankar Rajarethinam , Soo Yong Tan, Jian Jin , Augusto Villanueva , Eleftherios Michailidis , Ype P. De Jong, Charles M. Rice, Ivan Marazzi, Dan Hasson, Josep M. Llovet , Radoslaw M. Sobota , Amaia Lujambio , Ernesto Guccione & Arvin C. Dar Article Title: WNTinib is a multi-kinase inhibitor with specificity against β-catenin mutant hepatocellular carcinoma Article Snippet: .. Mutant kinase cloning Drug-resistant p38-alpha (Thr106Met) and BRAF (Thr529Asn) and constitutively active cKIT (Val599Asp, Thr670Ile) were made using overlapping primers via site-directed mutagenesis on Article Title: WNTinib is a multi-kinase inhibitor with specificity against β-catenin mutant hepatocellular carcinoma Article Snippet: .. Drug-resistant p38-alpha (Thr106Met) and BRAF (Thr529Asn) and constitutively active cKIT (Val599Asp, Thr670Ile) were made using overlapping primers via site-directed mutagenesis on Construct:Article Title: WNTinib is a multi-kinase inhibitor with specificity against β-catenin mutant hepatocellular carcinoma. Article Snippet: Alex Rialdi, Mary Duffy, Alex P. Scopton, Frank Fonseca, Julia Nanyi Zhao , Megan Schwarz, Pedro Molina-Sanchez, Slim Mzoughi, Elisa Arceci, Jordi Abril-Fornaguera , Austin Meadows, Marina Ruiz de Galarreta, Denis Torre, Kyna Reyes, Yan Ting Lim, Felix Rosemann , Zaigham M. Khan , Kevin Mohammed, Xuedi Wang, Xufen Yu , Manikandan Lakshmanan, Ravisankar Rajarethinam , Soo Yong Tan, Jian Jin , Augusto Villanueva , Eleftherios Michailidis , Ype P. De Jong, Charles M. Rice, Ivan Marazzi, Dan Hasson, Josep M. Llovet , Radoslaw M. Sobota , Amaia Lujambio , Ernesto Guccione & Arvin C. Dar Article Title: WNTinib is a multi-kinase inhibitor with specificity against β-catenin mutant hepatocellular carcinoma Article Snippet: .. Mutant kinase cloning Drug-resistant p38-alpha (Thr106Met) and BRAF (Thr529Asn) and constitutively active cKIT (Val599Asp, Thr670Ile) were made using overlapping primers via site-directed mutagenesis on Article Title: WNTinib is a multi-kinase inhibitor with specificity against β-catenin mutant hepatocellular carcinoma Article Snippet: .. Drug-resistant p38-alpha (Thr106Met) and BRAF (Thr529Asn) and constitutively active cKIT (Val599Asp, Thr670Ile) were made using overlapping primers via site-directed mutagenesis on Cloning:Article Title: WNTinib is a multi-kinase inhibitor with specificity against β-catenin mutant hepatocellular carcinoma Article Snippet: .. Mutant kinase cloning Drug-resistant p38-alpha (Thr106Met) and BRAF (Thr529Asn) and constitutively active cKIT (Val599Asp, Thr670Ile) were made using overlapping primers via site-directed mutagenesis on |

